Work

Importance of Drug Pharmacokinetics at the Site of Action

Year: 2017
Type: review
Abstract: Pharmacological activity depends on adequate drug levels at the effect site, but access to these sites for pharmacokinetic sampling is often limited. Thus, we often rely on plasma concentrations as surrogates in efforts to understand exposure–response relationships. Recent advances in analytical and quantitative methodologies allow for more robust and often noninvasive assessments of drug pharmacokinetics at the site of action. This review highlights the advances made in estimating drug exposures in several compartments of interest. Due to difficulty in accessing relevant tissues or biological fluids to measure drug levels, plasma drug concentrations are often collected with the hope that they will correlate with or be informative about exposures in compartments of interest, which is often found to be the case. Even between structurally similar compounds, however, penetration into these matrices may vary widely, and so exclusive use of plasma exposure in pharmacokinetic–pharmacodynamic (PK/PD) models may lead to suboptimal assessment of exposure–response relationships and inaccurate dose selection in certain circumstances. Differences in penetration between even structurally similar compounds into a given site may be due to a host of factors ranging from permeability to local metabolism to physicochemical properties to the role of drug transporters in efflux or uptake. Novel experimental and quantitative methods have been developed to assess drug levels at the site of action across therapies and disease areas. For central nervous system (CNS) diseases, the measurement of drug levels in the cerebrospinal fluid (CSF) using lumbar puncture and even directly in the brain using imaging or microdialysis has provided insight into drug penetration across the blood–brain barrier and helped characterize the compartmental pharmacology of such drugs. In oncology, linking information about drug penetration into solid tumors with radiologic outcomes provides a greater understanding of relevant exposure–response relationships. For HIV, characterization of drug distribution into the genital tract and the colorectum, sites of potential HIV exposure, has informed the development of preexposure prophylaxis. For antibacterials, lung penetration studies using microdialysis or invasive bronchiolar lavage have been instrumental in projecting drugs and doses with sufficient local exposure to be efficacious against the bacterial pathogens that cause pneumonia, while the assessment of PK in urine provides insight into the likelihood of successful treatment of urinary tract infections. As analytical and quantitative techniques have continued to evolve to allow for the assessment of drug levels at these various sites of action, so has our knowledge regarding the role of drug-metabolizing enzymes and transporters in the uptake and efflux of drugs in relevant compartments.1, 2 Our ability to assess the role a transporter may play in the distribution and elimination of a given drug has expanded with the development of increasingly complex in vitro systems and growing knowledge about how to translate such in vitro results to clinical impact. Together with quantitative approaches such as physiology-based pharmacokinetic (PBPK) modeling, we now have the tools at our disposal to predict drug disposition and how factors such as patient demographics, pharmacogenomics, or coadministration with other drugs affect it. There is a wealth of knowledge regarding the development and application of PBPK models that has been well described previously,3-5 both for small molecules and monoclonal antibodies.6, 7 With sufficient information about drug levels at the site of action, advances in population PK modeling can allow for the effect site to be treated as a separate compartment, thus bridging effect site PK to plasma PK. Once mathematical linkages between effect site and plasma PK are established, inferences about effect site PK can be made in subsequent experiments in which only plasma PK is collected, especially in cases where site-of-disease PK measurement is invasive or inconvenient. However, one must be careful to consider situations where nonlinearities may limit the ability to extrapolate plasma PK to tissue levels under different scenarios. Such limitations may arise due to saturation of drug transport pathways, nonlinear or concentration-dependent protein binding that differentially impacts fluids and tissues, or similarly nonlinear or concentration-dependent drug clearance. Additionally, often information regarding effect site PK is gathered in situations where limited sampling takes place. The dynamic changes in drug level in the plasma and effect site are often not synchronous, and thus sampling limitations may lead to an inadequate understanding of the relationship between plasma and effect site drug levels. Additionally, systems-level models such as quantitative systems pharmacology (QSP) and physiology-based pharmacodynamic (PBPD) models have progressed to enable linking the effect of drug levels at the site of action to the underlying causal biology.8, 9 Together, these quantitative approaches coupled with advances in sampling techniques allow for great advances in our ability to predict and describe the distribution of drugs in the body and the corresponding impact on disease modulation and treatment. However, it should be noted that each of these experimental and quantitative methodologies may come with significant effort, and thus the benefit of such approaches needs to be weighed against the utility of simpler methods. In many cases, fit-for-purpose translational models or the utilization of plasma PK may be perfectly suitable for the purpose at hand. Understanding PK at the site of action and demonstrating direct evidence of target engagement is not simply of scientific interest, but is also being increasingly recognized as key learning required to improve the yield of pharmaceutical research & development. Systematic reviews of drug discovery programs at large pharmaceutical companies have led to publication of translational risk frameworks, and obtaining adequate exposure at the intended site of action has been identified as a critical component of achieving downstream success in clinical trials.10, 11 Thus, the earlier one can demonstrate with confidence that a drug is present at the disease site, the higher the likelihood of observing the desired pharmacology for novel drug therapies. In this review, advances made in the estimation of drug exposures in several compartments of interest are discussed , as illustrated in Figure 1, including key biological considerations of each compartment and techniques utilized to gain insight into PK at the various sites of action, as described in Tables 1 and 2, respectively. The brain and the CSF are unique and difficult-to-access compartments. The blood–brain barrier (BBB) does an exquisite job of shielding the CNS from substances in the systemic circulation that are either nonessential or toxic. Tight junctions between capillary endothelial cells restrict paracellular diffusion, and most compounds that manage to enter (however briefly) are efficiently removed by efflux pumps.12 P-glycoprotein (P-gp, or MDR1) is the best-known transporter, but others, like breast cancer-resistant protein (BCRP), contribute to a highly redundant, efficient, and dynamic "waste" removal system.13 Drugs to treat CNS diseases such as brain cancer, meningitis, pain, psychiatric or neurodegenerative disorders must cross the BBB or blood–CSF (BCSF) barriers to be effective, and thus drug developers must outwit this highly evolved system. The ability of a drug to enter and remain in the CNS depends on several physicochemical properties—lipid solubility, ionization, molecular weight, the number of hydrogen bond donors, protein binding—and as predictive knowledge to assess these characteristics increases, scoring systems are being developed to assess a compound's drug-like properties for CNS penetration.14 Conversely, drugs intended for non-neurologic indications that readily enter the CNS may have off-target liabilities, such as efavirenz (HIV drug whose metabolite is directly neurotoxic and causes neurocognitive impairment) or cycloserine (anti-tuberculosis (TB) drug that is an NMDA agonist and provokes psychosis and symptoms of "irritability, hypocrisy and querulousness").15-17 For treatment of a disease of the brain or meninges, drugs must adequately penetrate into the brain and CSF when given at doses that are clinically safe. Knowledge of drug concentrations at the site of (on-target or off-target) action may be helpful in guiding PK/PD assessments that, in turn, direct drug dosing decisions. However, the brain and CSF are neither readily nor repeatedly accessible compartments, and given differences between drug clearance from plasma vs. CSF as well as variability in penetration of drugs to the brain and CSF related to inflammation and breakdown of vascular integrity, the dynamics of drug concentrations in CSF cannot generally be extrapolated from plasma concentration data or accurately estimated from a single CSF-to-plasma paired-sample ratio.18, 19 Moreover, CSF collected via lumbar puncture is often not a good proxy for drug concentrations in brain extracellular fluid (ECF) (drugs are pumped out of the brain into CSF, and CSF is produced cranially and then flows caudally).20 There are also differences between BBB and BCSF with regard to the molecular architecture of membrane transporters. For example, while Pgp is the most abundantly expressed transporter on the apical side of the BBB, MRP1 is predominantly expressed at the choroid plexus (CP), facing the interstitial fluid. On the other hand, Pgp is expressed at the CP, facing the CSF. Based on the transporter localization, it is suggested that MRP1 is critical at the CP in eliminating drugs.21, 22 Therefore, using CSF PK studies to assess CNS penetration could potentially be inaccurate if drugs targeting brain parenchyma interact differently with Pgp and MRP1. Up to now, CNS drug development has been fraught with peril, with CNS drugs taking an average of 18 years to progress from bench to bedside and only about an 8.2% success rate.23, 24 Late-stage failures abound, as CNS drugs tested in phase III trials are 45% less likely to be successfully registered than non-CNS drugs,25 mostly due to failure of efficacy. Clearly, more effective strategies to assess both drug exposures in the brain and, more important, biomarkers of drug activity at the site of disease early in clinical development are needed. Cerebral microdialysis has emerged as a very informative, albeit invasive, means of continuously measuring molecules in brain ECF (the fluid surrounding neurons and astrocytes).20 Microdialysis can be used in animal models (e.g., rat) to get an early look at drug penetration into the brain and CSF. While one would hope to be able to characterize plasma-CSF-brain drug distribution relationships in an animal model and then simply collect CSF in humans and use relationships discovered in the rat to predict human brain ECF concentrations, it is, in fact (not surprisingly), not so easy.26, 27 In general, characteristics of the BBB and BCSF are preserved across species and plasma-CSF and plasma-brain ECF distribution for drugs may be qualitatively similar in rats and humans; however, human CSF concentrations are generally higher than rat CSF concentrations and display higher variability (the latter may be, in part, because CSF in studies is only collected in patients with a brain or meningeal disease, whereas rat CSF is collected in healthy animals), and brain drug distribution PBPK models developed using rat data underestimate human CSF concentrations and often overestimate human brain ECF concentrations.26 Dynamic information about free drug concentrations in brain ECF and CSF generated via microdialysis in rats, however, can be used to build semimechanistic models and characterize processes such as active transport, intracellular partitioning, and local tissue binding for drugs of different types in the CNS (e.g., lipophilic passively transported only (acetaminophen28); lipophilic and PGP substrate (quinidine27); hydrophilic and MRP substrate (methotrexate29), etc.30). Then human- and drug-specific information can be added to the models (drug physicochemical properties, fluid flows, transporter functionalities, disease states) to improve their predictive power for estimating human brain ECF concentrations. Microdialysis is increasingly being used to monitor cerebral metabolism clinically in patients with traumatic brain injury,31 and techniques have been adapted to measure drug concentrations of putative neuroactive drugs in individuals requiring neurosurgery.20 As more human microdialysis data are generated, intraspecies differences in drug distribution in CNS compartments as well as effects of disease on CNS PK will increasingly be characterized, which will lead to better predictive models of human brain ECF concentrations.27 Positron emission tomography (PET) imaging has emerged as a noninvasive strategy for estimating CNS penetration of radiolabeled drugs. PET can also provide information about drug concentrations in specific regions of the brain known to have a high density of a receptor of interest (e.g., dopaminergic or serotonergic receptors for psychiatric drugs)32 or in areas of known brain disease (e.g., amyloid-beta-rich areas in patients with Alzheimer's disease or tumors).33 Functional neuroimaging, such as functional magnetic resonance imaging (fMRI), can be used throughout clinical development of CNS drugs, initially to demonstrate receptor occupancy in proof-of-concept studies,34 then subsequently to assess exposure–response relationships by measuring biomarkers of target engagement or drug effect in response to an administered drug,35 then finally to correlate drug exposure with brain structural features and function.36 With fMRI, participants with a disease of interest can be asked to perform specific tasks (in the presence or absence of the drug of interest or following a therapeutic trial), and fMRI activity in the affected area of the brain can be quantified. Small molecules and monoclonal antibodies are both employed in the treatment of cancer, either individually or, more often, in combination. Solid tumors are characterized by a complex and unique microenvironment that consists of infiltrating immune cells, low pH, a dense interstitial matrix, high interstitial pressure, and abnormal blood and lymphatic vascular structures.37, 38 Upregulation of vascular endothelial growth factor (VEGF), and chemokines such interleukin (IL)-8 and transforming growth factor (TGF)-beta1 by the tumors may trigger angiogenesis and increase vascular permeability and leakage.39 In vitro studies suggest that drug uptake and local concentrations are dependent on the density of the tumor and the distance from the rim and the tumor stroma.40 Variations in perfusion, vascularization, interstitial transport, and nonlinear local binding and metabolism can all contribute to differences in tumor PK among individuals, and each of these processes has been captured in mathematical models that describe drug distribution in the tumor.41 P-gp, BCRP, and transporters of the multidrug resistance-associated protein (MRP/ABCC) family have established roles in conferring multidrug resistance by limiting intracellular drug accumulation in tumor cells.42 Variability in drug penetration between patients has been demonstrated using molecular imaging with fluorescent or radiolabeled intact monoclonal antibodies or small molecules.43-47 Labeled molecules have been developed against a variety of drug targets, such as HER2, EGFR, insulin-like growth factor 1, androgen receptor, estrogen receptor, estradiol, and platelet-derived growth factor receptor B.48-50 Such molecular imaging techniques allow for increasingly precise and noninvasive methods of assessing targeted therapies. Microdialysis can be a useful tool for assessing tumor-specific free drug concentrations over the dosing interval in animal models and in accessible solid tumors in patients with cancer. Given that the therapeutic margin for chemotherapeutic drugs is generally very narrow, knowledge of site of action PK for anticancer drugs is particularly valuable for dose selection. Drug disposition at tumor sites, however, is often hard to predict without direct sampling, as blood flow and volume, expression and activity of transporters, and, very importantly, local environmental factors often differ greatly between tumors and surrounding normal tissue.51 Microdialysis, which is semiinvasive, allows sampling of free drug in the interstitial space of the tissue of interest at multiple postdose timepoints, which is more efficient and informative than the collection of tissue PK data at a single timepoint (e.g., at the time of sacrifice in animal models). Microdialysis has been best suited for small molecules, although recently probes have been introduced that also allow for the measurement of larger molecules.52 As previously reviewed by Zhou and Gallo,52 the utility of microdialysis as an approach relies on achieving adequate recovery of the analyte of interest, which may be impacted by a number of factors related to the probe, the tissue of interest, and the molecule of interest as well. Thus, each of these aspects should be taken into consideration when assessing the utility of microdialysis. Additionally, insertion of the microdialysis probe can disrupt the tumor microenvironment and impact drug distribution when care is not taken to allow for sufficient time for tissue to recover between samplings. Other macromolecules can be measured simultaneously in the tumor microenvironment, allowing for relevant site-of-disease treatment–response assessments.53-55 As the treatment of cancer continues to become more personalized or individualized, the ability to quantify drug levels and tumor properties, not only in each patient, but at each individual tumor, could allow for a greater degree of understanding of the interplay between the tumor microenvironment, genetics, and drug distribution, and how all of these factors interact to result in a given response. Microdialysis has been used to assess solid tumor PK of chemotherapeutic agents for melanoma, brain tumors,56, 57 ovarian cancer,58 and breast cancer,59 among others, in murine models or in patients with cancer and is useful in assessing targeted drug delivery strategies.60, 61 The complicated tumor microenvironment, where drug distribution is controlled by pharmacokinetic processes such as expression of drug transporters together with physical boundaries subject to fluid flow limitations such as blood flow and interstitial pressure, has led to the development of multiscale modeling approaches that bring together well-understood mathematical representations of fluid dynamics with physiologically-based PK models to capture and couple processes occurring at the molecular and systemic levels.62 As analytical, imaging, and computational approaches continue to evolve, the predictive power of such methods will continue to increase, allowing for more precise and accurate predictions of tumor drug penetration to enable personalized medicine approaches in oncology. Following decades of advances in the development of therapies for the treatment of HIV infection, recent clinical studies have demonstrated the utility of leveraging antiretroviral (ARV) agents for the prevention of HIV through preexposure prophylaxis (PrEP),63 leading to the approval of the combination of tenofovir disoproxil fumarate (TDF) and emtricitabine as to HIV in and results are by administered via a number of from to but only when they are and the of participants to treatment across For both the and where results but also very In several studies in where including the and demonstrated of This has also led to the development of novel of such as and that are to and thus Therefore, in to understand the potential for a to be effective for and, at the to gain information on PK measurement at the sites of potential exposure to HIV, the and genital tract is highly For an of drug levels of tenofovir in the fluid of participants in the a between PK in the and the level of against HIV with with tenofovir levels and with levels binding in the is to be with the of measured drug being While these results are regarding the utility of is limited biological or for these and more likely needs to be to robust PK/PD in these as previously local drug concentrations in an individual are a of both drug disposition in that individual and of PK. assessment of the exposure–response of tenofovir or other HIV is complicated by the fact that these agents are by intracellular so intracellular concentrations of the active drug are of most In the of intracellular tenofovir to the active tenofovir whose levels to be when assessing linkages between drug exposure and response. The PK of antiretroviral drugs measured in tissues is highly due both to patient and to the of drug metabolism and transport at these sites to thus plasma to be of limited as a for target site However, the measurement of tissue PK in the genital tract can invasive which the of data that can be and so is a greater on or population PK modeling to and the of fluids in recent studies has provided valuable information about local PK without the for invasive the collection of fluid via direct provides insight into drug concentrations in the genital while the collection of fluid via similarly provides insight into concentrations in the The between drug levels in these fluids and the surrounding tissues in one to use of local fluid as a for tissue fluid levels with corresponding tissue levels, they may potentially be used as a for the measurement of effect site PK. However, is limited information regarding protein binding in these tissues, which may limit of such data in the of related plasma concentration PK of drugs for HIV prevention may that are more likely to benefit from their For tenofovir exposures are higher in than while levels are similar to cause one to that at risk for HIV via may be more to differences in than have with are at risk to HIV through and results of the in demonstrated even with while the in in which in understanding the PK/PD relationship for HIV prevention using advances in animal and clinical models have been Our understanding of differences in drug metabolism and transport increasingly allows to predict and understand differences in antiretroviral penetration into and The expression of enzymes in the and tissues has been and a recent this a the activity of and enzymes through dosing of and as probe given the interest in these compounds for use as for HIV activity present in both the and and activity present in the Additionally, the found that the metabolite for in the and fluids different than in the plasma or that expression levels of and enzymes in tissues may differ from in the growing body of knowledge regarding the activity of drug transporters in the genital tract and is also a greater understanding of PK at the site of action. recent of efflux and uptake transporters in these tissues of interest provides an of the body of to from this that drug transport can play a role in the tissue distribution of antiretroviral drugs. predictive model data from drugs demonstrated that the penetration to could be and that this dependent on or not the drug a substrate of drug efflux transporters MRP1 and Additionally, P-gp, BCRP, and have all been found to be expressed the genital while P-gp, BCRP, and MRP1 through are all expressed in human tissue at levels higher than or to expression in the The activity of these transporters is by factors such as disease and administered drugs, which may provide for the large variability in studies that have measured tissue PK of for HIV and in turn, suggest that an understanding of drug transport is to predict tissue from the clinical trials in HIV together with advances in our understanding of drug metabolism and transport, suggest that may be the through advances in animal clinical and quantitative to our ability to predict the for the population to HIV resistance is an and now an The of bacterial and has and for the development of therapies. In advances in and have to understand at a more level the to the of This in turn, allows for a more understanding of dose and of which therapies are most likely to be not only effective at the but also robust against can be by both and is most by the while and are the most causes of or resistance can be a when patients with pneumonia, and dosing must be high to the of methods have been used to drug concentrations of agents in the including lavage fluid and magnetic resonance There are various and of each of the methods that must be when an For pathogens may in the extracellular or intracellular For extracellular the is the site of action and is a where protein binding a limited role and the drug in the free or For intracellular are as the site of interest. Thus, knowledge of the of the under may impact the of measurement Additionally, approaches such as may differences in the penetration of drug vs. or between different
Language: English
Subfield: Pharmacology
Open Access status: gold
Estimated APC paid: $3,630
OpenAlex ID: W2583770167
FWCI: 1.893
Cites: 108
Cited by: 149
Related to: 10